Davidr Guyer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Monashee Investment Management LLC bought a new stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 175,000 shares of the company’s stock, valued at approximately $4,044,000. EyePoint Pharmaceuticals accounts for about 0.7% of Monashee […]

In addition to augmenting Merck’s pipeline, the company said, the acquisition significantly expands the company’s presence in ophthalmology.

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report)’s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $11.16, but opened at $10.90. EyePoint Pharmaceuticals shares last traded at $11.13, with a volume of 79,034 shares. Analyst Ratings Changes Several research analysts have recently issued reports on the company. […]

In a report released today, Yuan Zhi from B.Riley Financial reiterated a Hold rating on IVERIC bio (ISEE – Research Report), with a price ...